NEW BRUNSWICK, NJ — February 22, 2002 — The monoclonal antibody infliximab has been shown to provide a rapid, durable response and a high level of sustained efficacy for at least six months in patients with moderate-to-severe psoriasis, according to new long-term data presented today at the 60th Annual Meeting of the American Academy of Dermatology (AAD).
SOURCE: University of Medicine & Dentistry of New Jersey
לכתבה המלאה הקליקו על הקישור
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!